{"id":"NCT05033743","sponsor":"Indiana University","briefTitle":"Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study","officialTitle":"Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2021-07-09","primaryCompletion":"2022-10-07","completion":"2022-10-07","firstPosted":"2021-09-05","resultsPosted":"2024-02-05","lastUpdate":"2024-02-05"},"enrollment":24,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Recurrent Bacterial Vaginosis"],"interventions":[{"type":"DRUG","name":"Secnidazole 2 GM Oral Granules","otherNames":[]}],"arms":[{"label":"Treatment Group","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to test the effectiveness Secnidazole to treat recurrent BV. Secnidazole is approved for one-time use in acute BV. In this study, the drug will be used for recurrent BV, and given weekly for 18 weeks.","primaryOutcome":{"measure":"Number of Subjects With at Least One Episode of Bacterial Vaginosis","timeFrame":"30 weeks","effectByArm":[{"arm":"Treatment Group","deltaMin":8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":24},"commonTop":["Yeast Infection","Headache","Loose Stool","UTI","Nausea"]}}